Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
US7410991B2 · kind B2 · utility
7Cited by
5References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 23, 2002 |
| Grant date | Aug 12, 2008 |
| Priority date | — |
| Expiry date | May 24, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D231/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.